Retinopathy
1
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
MediBeaconGermany - Mannheim
1 program1
Fluorescein sodium and Zeiss FF450 fundus cameraPhase 11 trial
Active Trials
AstraZenecaCAMBRIDGE, United Kingdom
1 programManagement of Diabetes Mellitus Patients With RetinopathyN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
MediBeaconFluorescein sodium and Zeiss FF450 fundus camera
AstraZenecaManagement of Diabetes Mellitus Patients With Retinopathy
Clinical Trials (2)
Total enrollment: 2,510 patients across 2 trials
Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium
Start: Nov 2025Est. completion: Dec 202610 patients
Phase 1Recruiting
Management of Diabetes Mellitus Patients With Retinopathy
Start: Dec 2008Est. completion: Aug 20092,500 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 2,510 patients
2 companies competing in this space